-
公开(公告)号：US20250122307A1
公开(公告)日：2025-04-17
申请号：US18669172
申请日：2024-05-20
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Aynur Hermann , Ella IOFFE , Elena BUROVA , Gavin THURSTON , William OLSON
Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20240293566A1
公开(公告)日：2024-09-05
申请号：US18572930
申请日：2022-06-21
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Frank DELFINO , Marcus KELLY , Jessica KIRSHNER , Thomas NITTOLI , Gavin THURSTON
CPC classification number: A61K47/68035 , A61K45/06 , A61K47/6849 , A61P35/00
Abstract: The present disclosure provides antibody-drug conjugates (ADCs) comprising antibodies that bind to the class III variant of EGFR (EGFRVIII) conjugated to tesirine, and methods of using the same. According to certain embodiments, the antibodies or antigen-binding fragments thereof, useful herein, bind human EGFRVIII with high affinity. The antibodies or antigen-binding fragments thereof, useful herein, may be fully human antibodies. The ADCs provided herein are useful for the treatment of various cancers.
-
公开(公告)号：US20190284277A1
公开(公告)日：2019-09-19
申请号：US16433263
申请日：2019-06-06
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Erica ULLMAN , Aynur HERMANN , Ella IOFFE , Elena BUROVA , Gavin THURSTON
IPC: C07K16/28 , A61K39/395 , A61K45/06
Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
-
14.发明申请公开(公告)号：US20170174779A1
公开(公告)日：2017-06-22
申请号：US15386453
申请日：2016-12-21
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Bindu VARGHESE , Gavin THURSTON , Israel LOWY , Carrie BROWNSTEIN
IPC: C07K16/28 , A61K45/06 , A61K39/395 , C07K16/30
CPC classification number: C07K16/2887 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/3061 , C07K2317/31 , C07K2317/565
Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.
-
公开(公告)号：US20160251442A1
公开(公告)日：2016-09-01
申请号：US15051580
申请日：2016-02-23
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Nicholas J. PAPADOPOULOS , Gavin THURSTON , Jessica R. KIRSHNER , Marcus P. KELLY , Thomas NITTOLI , Frank J. DELFINO
CPC classification number: C07K16/2866 , A61K31/537 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
-
Patent Agency Ranking
公开(公告)号：US20210147557A1
公开(公告)日：2021-05-20
申请号：US16918656
申请日：2020-07-01
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K47/68 , C07K16/30
Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
-
公开(公告)号：US20210040232A1
公开(公告)日：2021-02-11
申请号：US17070129
申请日：2020-10-14
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Aynur HERMANN , Ella IOFFE , Elena BUROVA , Gavin THURSTON , William OLSON
Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20190048096A1
公开(公告)日：2019-02-14
申请号：US16046551
申请日：2018-07-26
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Aynur HERMANN , Ella IOFFE , Elena BUROVA , Gavin THURSTON , William OLSON
Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20180312594A1
公开(公告)日：2018-11-01
申请号：US16033477
申请日：2018-07-12
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jessica R. KIRSHNER , Douglas MACDONALD , Gavin THURSTON , Joel H. MARTIN , Frank DELFINO , Thomas NITTOLI , Marcus KELLY
Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
-
20.发明申请公开(公告)号：US20180236070A1
公开(公告)日：2018-08-23
申请号：US15959595
申请日：2018-04-23
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Ella IOFFE , Israel LOWY , Gavin THURSTON , Elena BUROVA
IPC: A61K39/395 , A61K9/00
Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.022 seconds)
